EXPO vs. G, AMEH, FCN, DNB, CBZ, ICFI, HURN, VSEC, CRAI, and ACTG
Should you be buying Exponent stock or one of its competitors? The main competitors of Exponent include Genpact (G), Apollo Medical (AMEH), FTI Consulting (FCN), Dun & Bradstreet (DNB), CBIZ (CBZ), ICF International (ICFI), Huron Consulting Group (HURN), VSE (VSEC), CRA International (CRAI), and Acacia Research (ACTG).
Exponent (NASDAQ:EXPO) and Genpact (NYSE:G) are both mid-cap business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, community ranking, institutional ownership, profitability, dividends and analyst recommendations.
Exponent pays an annual dividend of $1.12 per share and has a dividend yield of 1.2%. Genpact pays an annual dividend of $0.61 per share and has a dividend yield of 1.8%. Exponent pays out 56.6% of its earnings in the form of a dividend. Genpact pays out 17.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Genpact is clearly the better dividend stock, given its higher yield and lower payout ratio.
Exponent has a net margin of 18.72% compared to Genpact's net margin of 14.21%. Exponent's return on equity of 28.13% beat Genpact's return on equity.
Genpact received 183 more outperform votes than Exponent when rated by MarketBeat users. Likewise, 68.30% of users gave Genpact an outperform vote while only 63.09% of users gave Exponent an outperform vote.
Genpact has higher revenue and earnings than Exponent. Genpact is trading at a lower price-to-earnings ratio than Exponent, indicating that it is currently the more affordable of the two stocks.
In the previous week, Genpact had 3 more articles in the media than Exponent. MarketBeat recorded 12 mentions for Genpact and 9 mentions for Exponent. Exponent's average media sentiment score of 1.11 beat Genpact's score of 0.65 indicating that Exponent is being referred to more favorably in the media.
92.4% of Exponent shares are held by institutional investors. Comparatively, 96.0% of Genpact shares are held by institutional investors. 2.1% of Exponent shares are held by company insiders. Comparatively, 2.8% of Genpact shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Exponent has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Genpact has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
Exponent currently has a consensus target price of $100.00, suggesting a potential upside of 6.97%. Genpact has a consensus target price of $38.00, suggesting a potential upside of 13.98%. Given Genpact's higher probable upside, analysts clearly believe Genpact is more favorable than Exponent.
Summary
Genpact beats Exponent on 12 of the 19 factors compared between the two stocks.
Get Exponent News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXPO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exponent Competitors List
Related Companies and Tools
